REVIEW PAPER
Biomarkers of intestinal epithelial damage in children with food allergies
1
Department of Pediatrics, Gastroenterology, Hepatology, Nutrition and Allergology, Medical University of Bialystok, Bialystok, Poland
Submission date: 2019-05-21
Final revision date: 2019-07-10
Acceptance date: 2019-07-16
Publication date: 2019-08-30
Pediatr Pol 2019;94(4):248-254
KEYWORDS
TOPICS
ABSTRACT
Food allergy has a significant negative impact on patients and their families, and it has become an important public health problem. Currently used diagnostic methods, such as skin prick tests (SPT) and determination of specific immunoglobulins E (sIgE), present limited sensitivity and specificity. Therefore, new tools are expected to improve the accuracy of the diagnostic work-up. A recent hypothesis of allergic reactions indicates a primary role of dysregulation of the epithelial barrier, which pioneers the role of biomarkers of intestinal damage in food allergy. The objective of this paper is to present the currently most promising biomarkers for the diagnosis, prognosis, and management of food allergy in children.
REFERENCES (60)
1.
Zissler UM, Esser‐von Bieren J, Jakwerth CA, et al. Current and future biomarkers in allergic asthma. Allergy 2016; 71: 475-494.
2.
Siddiqui I, Majid H, Abid S. Update on clinical and research application of fecal biomarkers for gastrointestinal diseases. World J Gastrointest Pharmacol Ther 2017; 8: 39-46.
3.
Muraro A, Werfel T, Hoffmann-Sommergruber K, et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy 2014; 69: 1008-1025.
4.
Kaczmarski M, Wasilewska J, Jarocka-Cyrta E, et al. Polskie stanowisko w sprawie alergii pokarmowej u dzieci i młodzieży. Post Dermatol Alergol 2011; 28: 75-115.
5.
Cudowska B, Lebensztejn DM. Zapalenie jelit indukowane białkami pokarmowymi u dzieci. Gastroenterol Prakt 2017; 1: 43-45.
6.
Chehade M, Mayer L. Oral tolerance and its relation to food hypersensitivities. J Allergy Clin Immunol 2005; 115: 3-12.
7.
Schurink M, Kooi EM, Hulzebos CV, et al. Intestinal Fatty Acid-Binding Protein as a Diagnostic Marker for Complicated and Uncomplicated Necrotizing Enterocolitis: A Prospective Cohort Study. PLoS One 2015; 10: e0121336.
8.
Anderson RC, Cookson AL, McNabb WC, et al. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol 2010; 10: 316.
9.
Ewaschuk J, Diaz H, Meddings L, et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol 2008; 295: 1025-1034.
10.
Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011; 469: 543-547.
11.
Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104-119.
12.
Arrieta MC, Bistritz L, Meddings JB, et al. Alterations in intestinal permeability. Gut 2006; 55: 1512-1520.
13.
Mattila P, Joenväärä S, Renkonen J, et al. Allergy as an epithelial barrier disease. Clin Transl Allergy 2011; 1: 5.
14.
WHO International Programme on Chemical Safety Biomarkers in Risk Assessment: Validity and Validation 2001. http://www.who.int/iris/handle....
15.
Byrnes SA, Weigl BH. Selecting analytical biomarkers for diagnostic applications: a first principles approach. Expert Rev Mol Diagn 2018; 18: 19-26.
16.
Bischoff SC, Giovanni B, Buurman W, et al. Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterol 2014; 14: 189.
17.
Anderson AD, Jain PK, Fleming S, et al. Evaluation of a triple sugar test of colonic permeability in humans. Acta Physiol Scand 2004; 182: 171-177.
18.
van Wijck K, Verlinden TJ, van Eijk HM, et al. Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: a randomized controlled crossover trial. Clin Nutr 2013; 32: 245-251.
19.
DeMeo MT, Mutlu EA, Keshavarzian A, et al. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 2002; 34: 385-396.
20.
Denno DM, VanBuskirk K, Nelson ZC, et al. Use of the Lactulose to Mannitol Ratio to Evaluate Childhood Environmental Enteric Dysfunction: A Systematic Review. Clin Infect Dis 2014; 59: 213-219.
21.
Vilela EG, Torres HO, Ferrari ML, et al. Gut permeability to lactulose and mannitol differs in treated Crohn’s disease and celiac disease patients and healthy subjects. Braz J Med Biol Res 2008; 41: 1105-1109.
22.
Boyle RJ, Hardikar W, Tang ML. The development of food allergy after liver transplantation. Liver Transpl 2005; 11: 326-330.
23.
Kalach N, Kapel N, Waligora-Dupriet AJ. Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow’s milk allergy in toddlers. Clin Chem Lab Med 2013; 51: 351-361.
24.
Diamanti A, Panetta F, Gandullia P, et al. Plasma citrulline as marker of bowel adaptation in children with short bowel syndrome. Langenbecks Arch Surg 2011; 396: 1041-1046.
25.
Crenn P, Vahedi K, Lavergne-Slove A, et al. Plasma citrulline: A marker of enterocyte mass in villous atrophy-associated small bowel disease. Gastroenterology 2003; 124: 1210-1219.
26.
Barzał JA, Szczylik C, Rzepecki P, et al. Plasma citrulline level as a bio-marker for cancer therapy-induced small bowel mucosal damage. Acta Biochim Pol 2014; 61: 615-631.
27.
Ioannou HP, Diamanti E, Piretzi K, et al. Plasma citrulline levels in preterm neonates with necrotizing enterocolitis. Early Hum Dev 2012; 88: 563-566.
28.
Lutgens LC, Blijlevens NM, Deutz NE, et al. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer 2005; 103: 191-199.
29.
Konstantinos CF, Alastair F. Citrulline as a marker of intestinal function and absorption in clinical settings: A systematic review and meta-analysis. United European Gastroenterol J 2018; 6: 181-191.
30.
Singh A, Verma A, Das P, et al. Non-Invasive Biomarkers for Assessment of Villous Abnormalities in Patients with Celiac Disease and Other Enteropathies: An Alternative to Mucosal Biopsies. Gastroenterology 2017; 152: 264.
31.
Coufal S, Kokesova A, Tlaskalova-Hogenova H, et al. Urinary Intestinal Fatty Acid-Binding Protein Can Distinguish Necrotizing Enterocolitis from Sepsis in Early Stage of the Disease. J Immunol Res 2016; 2016: 5727312.
32.
Derikx JP, Blijlevens NM, Donnelly JP, et al. Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic stem-cell transplant recipients. Ann Oncol 2009; 20: 337-342.
33.
Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterology 2014; 14: 189.
34.
Adriaanse MP, Tack GJ, Passos VL, et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther 2013; 37: 482-490.
35.
Zhang YW, Ding LS, Lai MD. Reg gene family and human diseases. World J Gastroenterol 2003; 9: 2635-2641.
36.
Yoshimoto K, Fujimoto T, Itaya-Hironaka A, et al. Involvement of autoimmunity to REG, a regeneration factor, in patients with primary Sjögren’s syndrome. Clin Exp Immunol 2013; 174: 1-9.
37.
Planas R, Pujol-Autonell I, Ruiz E, et al. Regenerating gene Iα is a biomarker for diagnosis and monitoring of celiac disease: a preliminary study. Transl Res 2011; 158: 140-145.
38.
Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 2000; 356: 1783-1784.
39.
Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull 2003; 26: 753-760.
40.
Bunn SK, Bisset WM, Main MJ, et al. Fecal Calprotectin: Validation as a noninvasive Measure of Bowel Inflammation in Childhood Inflammatory Bowel Disease. J Pediatr Gastroentreol Nutr 2001; 33: 14-22.
41.
Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009; 41: 56-66.
42.
Dhaliwal A, Zeino Z, Tomkins C, et al. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol 2015; 6: 14-19.
43.
Herra OR, Christensen ML, Helms RA. Calprotectin: Clinical Applications in Pediatrics. J Pediatr Pharmacol Ther 2016; 21: 308-321.
44.
Ezri J, Nydegger A. Pediatrics. Fecal calprotectin in children: use and interpretation. Rev Med Suisse 2011; 7: 69-70.
45.
Waligora-Dupriet AJ, Campeotto F, Romero K. Diversity of gut Bifidobacterium species is not altered between allergic and non-allergic French infants. Anaerobe 2011; 17: 91-96.
46.
Daniluk U, Daniluk J, Krasnodebska M, et al. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn’s disease. Adv Med Sci 2018; 64: 9-14.
47.
Beşer ÖF, Sancak S, Erkan T, et al. Can Fecal Calprotectin Level Be Used as a Markers of Inflammation in the Diagnosis and Follow-Up of Cow’s Milk Protein Allergy? Allergy Asthma Immunol Res 2014; 6: 33-38.
48.
Kukkonen K, Kuitunen M, Haahtela T. High intestinal IgA associates with reduced risk of IgE-associated allergic diseases. Pediatr Allergy Immunol 2010; 21: 67-73.
49.
Rosenberg HF. Eosinophil-derived Neurotoxin/RNase 2: connecting the past, the present and the future. Curr Pharm Biotechnol 2008; 9: 135-140.
50.
Rosenberg HF, Domachowke JB. Eosinophils, eosinophil ribonucleases, and their role in host defence against respiratory virus pathogens. J Leukoc Biol 2001; 70: 691-698.
51.
Kim CK, Callaway Z, Park JS, et al. Utility of serum eosinophil-derived neurotoxin (EDN) measurement by ELISA in young children with asthma. Int Allerg 2017; 66: 70-74.
52.
Majamaa H, Laine S, Miettinen A. Eosinophil protein X and eosinophil cationic protein as indicators of intestinal inflammation in infants with atopic eczema and food allergy. Clin Exp Allergy 1999; 29: 1502-1506.
53.
Ada T, Toma T, Muraoka M. Elevation of fecal eosinophil-derived neurotoxin in infants with food protein-induced enterocolitis syndrome. Pediatr Allergy Immunol 2014; 25: 617-619.
54.
Morita H, Nomura I, Shoda T. Fecal Eosinophil- derived neurotoxin is significantly elevated in non- IgE dependent Gastrointestinal allergies, especially in subtypes showing bloody stool [abstract]. J Allergy Clin Immunol 2012; 129: A353.
55.
Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012; 119: 651-665.
56.
Heyman M, Darmon N, Dupont C, et al. Mononuclear cells from infants allergic to cow’s milk secrete tumor necrosis factor alpha, altering intestinal function. Gastroenterology 1994; 106: 1514-1523.
57.
Rodriguez P, Heyman M, Candalh C, et al. Tumour necrosis factor-alpha induces morphological and functional alterations of intestinal HT29 cl.19A cell monolayers. Cytokine 1995; 7: 441-448.
58.
Chung HL, Hwang JB, Park JJ, et al. Expression of transforming growth factor beta1, transforming growth factor type I and II receptors, and TNF-αlpha in the mucosa of the small intestine in infants with food protein-induced enterocolitis syndrome. J Allergy Clin Immunol 2002; 109: 150-154.
59.
Wada H, Horisawa T, Inoue M, et al. Sequential measurement of fecal parameters in a case of non-immunoglobulin E-mediated milk allergy. Pediatr Int 2007; 49: 109-111.
60.
Morita H, Nomura I, Orihara K, et al. Antigen-specific T-cell responses in patients with non-IgE-mediated gastrointestinal food allergy are predominantly skewed to T(H)2. J Allergy Clin Immunol 2013; 131: 590-592.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
